^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | vididencel (DCP-001) (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)
Published date:
09/08/2023
Excerpt:
Mendus AB...announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the Company’s lead program, vididencel, for the treatment of Acute Myeloid Leukemia (AML) in complete remission with residual disease.
